Summary
The pharmacokinetics of atenolol were determined following acute intravenous and chronic oral administration to 20 subjects with a glomerular filtration rate (GFR) between 5 and 113 ml/min. Plasma levels in a further 5 patients on haemodialysis were measured after intravenous treatment. The mean half life of elimination increased from 5.9 h in patients with normal renal function to 42.1 h in preuraemic patients (GFR <10 ml/min) following a single i. v. dose. The half life of elimination following chronic oral administration was not significantly different. Mean peak plasma concentrations increased from 540 ng/ml in patients with normal renal function to 1493 ng/ml in preuraemic patients following chronic oral treatment with 100 mg/day. The mean half life of elimination during a single haemodialysis treatment was 4.3 h. In patients with a GFR >30 ml/min the normal daily dose of atenolol should be employed, in patients with a GFR between 10 and 30 ml/min the dose should be reduced by half, and in patients with a GFR <10 ml/min a reduction by three quarters of the normal dose is recommended.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Abendroth RR, Husmann W, Stephan K, Schley G, Hübner H (1977) Wirkung des β-Sympatholytikums Atenolol auf die Arrhythmie, speziell das Kammerflimmern und die Flimmerschwelle des Herzens beim akuten experimentellen Herzverschluß. Z Kardiol 66: 341–350
Barrett AM, Carter J, Fitzgerald JD, Hull R, Lecount D (1973) A new type of cardioselective adrenoceptive blocking drug. Br J Pharmacol 48: 340 P
Brown HC, Carruthers SG, Johnston GD, Kelly JG, McAinsh J, McDevitt DG, Shanks RG (1976) Clinical pharmacologic observations on atenolol, a beta-adrenoceptor blocker. Clin Pharmacol Ther 20: 524–534
Conolly ME, Kersting F, Dollery CT (1976) The clinical pharmacology of beta-adrenoceptor blocking drugs. Prog Cardiovasc Dis 19: 203–234
Decalmer PBS, Chatterjee SS, Cruickshank J, Benson MK, Sterling GM (1978) Beta-blockers and asthma. Br Heart J 40: 184–189
Eriksen J, Osnik K, Bedieten J (1977) Atenolol in the treatment of angina pectoris. Acta Med Scand 201: 579–584
Schley G, Beckmann R, Hengstebeck W (1978) Die Behandlung von akuten Herzrhythmusstörungen mit Atenolol (Tenormin®) speziell beim Herzinfarkt. Z Kardiol 67: 280–288
Mason WD, Winer N, Kochak G, Cohen I, Bell R (1979) Kinetics and absolute bioavailability of atenolol. Clin Pharmacol Ther 25: 408
Conway FJ, Fitzgerald JD, McAinsh J, Rowland DJ, Simpson WT (1976) Human pharmacokinetic and pharmacodynamic studies on atenolol (ICI 66, 082), a new cardioselective β-adrenoceptor blocking drug. Br J Clin Pharmacol 3: 267–272
Koda RT, Maronde RF, Wan SH, Malbica J, Lesky W (1977) Kinetics of absorption and excretion of atenolol (ICI 66, 082) from single intravenous and oral doses in humans. Clin Pharmacol Ther 21: 108
McAinsh J (1977) Clinical pharmacokinetics of atenolol. Postgrad Med J 53: Suppl 3, 74–78
Sassard J, Pozet N, McAinsh J, Legheand J, Zech P (1977) Pharmacokinetics of atenolol in patients with renal impairment. Eur J Clin Pharmacol 12: 175–180
Niedermayer W, Seiler K-U, Wassermann O (1978) Pharmacokinetics of antihypertensive drugs (atenolol, metoprolol, propranolol and clonidine) and their metabolites during intermittent hemodialysis in humans. XV. Congr. EDTA, Istanbul
Milutinovic J, Cutter RE, Hoover P, Hujesin B, Scribner BH (1975) Measurement of residual glomerular filtration rate in the patients receiving repetitive hemodialysis. Kidney Int 8: 185–190
Schäfer M, Mutschler E (1979) Fluorimetric determination of atenolol in plasma and urine by direct evaluation of thin-layer chromatograms. J Chromatogr 169: 477–481
Reeves PR, McAinsh J, McIntosh DAD, Winrow MJ (1978) Metabolism of atenolol in man. Xenobiotica 8: 313–320
Øie S, Levy G (1975) Relationship between renal function and elimination kinetics of pindolol in man. Eur J Clin Pharmacol 9: 115–116
Welling PG, Craig WA (1976) Pharmacokinetics in disease states modifying renal function. 123rd Annual Meeting of American Pharmacological Association, New Orleans
Thompson FD, Joekes AM, Foulkes DM (1977) Pharmacodynamics of propranolol in renal failure. Br Med J 2: 434–436
Dettli L (1977) Elimination kinetics and dosage adjustment of drugs in patients with kidney disease. Prog Pharmacol 1: (4)
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kirch, W., Köhler, H., Mutschler, E. et al. Pharmacokinetics of atenolol in relation to renal function. Eur J Clin Pharmacol 19, 65–71 (1981). https://doi.org/10.1007/BF00558387
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00558387